TokenPost·
SELLAS Shares Rise More Than 200% After Leukemia Vaccine Meets Trial Goal

Median survival was 24.0 months for patients receiving galinpepimut-S, compared with 14.7 months for the comparison group.
Every crypto headline. One feed. Updated every minute.

Median survival was 24.0 months for patients receiving galinpepimut-S, compared with 14.7 months for the comparison group.